廣告

Regeneron's antibody drug shows protection against COVID-19

Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period following the drug's administration.

影片文字轉錄稿

[MUSIC PLAYING]